CLINICAL TRIAL SUMMARY

MDACC Study No:2005-0574 (clinicaltrials.gov NCT No: NCT00489008)
Title:Phase II stereotactic body radiotherapy for stage I (T1-T2, N0, M0), selective stage II (chest wall T3, N0M0) or isolated peripheral lung recurrent Non-Small Cell Lung Cancer (NSCLC)
Principal Investigator:Joe Y. Chang
Treatment Agent:Radiation
Study Status:Closed
Study Description:The goal of this clinical research study is to learn if stereotactic body
radiotherapy (SBRT) can help to control NSCLC. The safety of SBRT will also be
studied.

Hide details for General InformationGeneral Information

Disease Group:Lung
Phase of Study:Phase II
Treatment Agents:Radiation
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:n/a
Supported By:N/A
Return Visit:Patients will be followed 6 weeks after RT and then every 3 months for two
years. For this protocol purpose, we are going to follow patients for minimal
two years to finish this protocol.
Home Care:n/a


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Joe Y. Chang
Dept:Radiation Oncology
For Clinical Trial Enrollment:713-563-2300
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults